Towa Pharmaceutical (4553) Q3 2025 earnings summary

Executive summary

• Consolidated net sales rose 15.1% year-over-year to JPY 193.7 billion, with operating profit up 40.9% to JPY 18.6 billion and net profit attributable to owners up 27.0% to JPY 14.6 billion, driven by strong domestic demand and a weaker yen boosting overseas sales.

• Comprehensive income reached JPY 16.04 billion, up 7.8% year-over-year.

• Progress toward full-year targets is strong, with net sales at 73.9% and operating profit at 79.9% of plan.

Financial highlights

• Gross profit improved 17.1% year-over-year to JPY 70.74 billion, with gross margin expansion.

• Cost of sales increased 14.0% year-over-year, SGA expenses up 10.4%.

• Earnings per share increased to JPY 297.10 from JPY 234.03 year-over-year.

• Ordinary profit rose 26.7% to JPY 21.8 billion.

• Cash and cash equivalents at period-end were JPY 29.23 billion, down JPY 419 million from the previous year.

Outlook and guidance

• Full-year net sales forecast is JPY 262.1 billion (up 15.0% year-over-year), with operating profit projected at JPY 23.3 billion (up 32.0%).

• Annual dividend forecast raised to 70 yen per share.

• Full-year production volume expected at 14.2 billion tablets.